Actelion reports hypertension data amid Idorsia spinout

In a pipeline update outlining candidates it plans to spin out into newco Idorsia Ltd., Actelion Ltd. (SIX:ATLN) said ACT-132577 led to "statistically significant dose-dependent" reductions in both diastolic and systolic blood pressure in a Phase

Read the full 361 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE